CD8A and neoplasm: The delivered dose of RT also affects the anti-tumor response: a dose >2 Gy induces higher tumor antigens spreading and has been described to be associated with the generation of effective and durable CD8+ T cell-mediated immune response, resulting in local and distal tumor control (18).